| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Curis Inc is a biotechnology company that focusses on developing innovative cancer therapies. Founded in 2000, the company is headquartered in Lexington, Massachusetts. Curis has a strategic collaboration with Aurigene and is known for its expertise in precision medicine and small molecule drug development.
The company's primary goal is to discover and develop novel targeted therapies for the treatment of various cancers. They utilize a proprietary drug discovery platform to identify potential drug candidates, focusing on signaling pathways and targeted proteins that play crucial roles in tumor growth and survival.
Curis has several drug candidates in its pipeline, with some in various stages of clinical development. Their lead candidate, CUDC-907, is being evaluated for the treatment of hematological cancers such as lymphoma. The company also has collaborations with other pharmaceutical companies to advance the development of their drug candidates.
Curis has a dedicated team of scientists and researchers who work towards translating scientific discoveries into potential cancer treatments. The company aims to bring innovative therapies to patients and improve outcomes in oncology.
In summary, Curis Inc is a biotechnology company that specializes in the development of targeted cancer therapies. With a focus on precision medicine and small molecule drug development, the company aims to make a significant impact in the field of oncology.
Company Address: 128 Spring Street Lexington 2421 MA
Company Phone Number: 503-6500 Stock Exchange / Ticker: NASDAQ CRIS
|
